{"result": {"id": "chatcmpl-581", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"Community Eye Health Research\",\n    \"summary\": \"This report analyzes the interconnected entities within the community focused on eye health research, particularly in the context of neovascular age-related macular degeneration (nAMD). The community comprises researchers, clinicians, and patients who are actively engaged in understanding, treating, and preventing this debilitating condition.  The report highlights key relationships between these entities, their impact on patient care, and potential future directions for research.\",\n    \"rating\": 8.0,\n    \"rating_explanation\": \"This community's impact is significant due to the high prevalence of nAMD and its profound effects on patients' quality of life. The research efforts within this community directly contribute to improving treatment options and potentially finding cures for this disease.\",\n    \"findings\": [\n        {\n            \"summary\": \"The primary focus of the community is on understanding and treating nAMD, a leading cause of vision loss in older adults.\",\n            \"explanation\": \"The research within this community centers around nAMD, a complex eye condition that affects the central vision.  It's characterized by abnormal blood vessel growth in the macula (the part of the retina responsible for sharp central vision). This leads to blurred or distorted vision and can significantly impact daily life. The community's efforts are directed towards developing new treatments and therapies to manage this condition effectively.\"\n        },\n        {\n            \"summary\": \"Clinical trials play a crucial role in advancing nAMD treatment options.\",\n            \"explanation\": \"Clinical trials are essential for testing the efficacy and safety of new drugs and therapies.  These trials involve patients with nAMD who participate in carefully designed studies to evaluate the effectiveness of different treatments. The community's focus on clinical trials ensures that new treatments are rigorously tested before being made available to patients.\"\n        },\n        {\n            \"summary\": \"Researchers are actively exploring novel treatment strategies for nAMD.\",\n            \"explanation\": \"The research within this community is focused on developing innovative and targeted therapies.  This includes investigating the use of gene therapy, stem cell therapy, and other cutting-edge approaches to address the underlying causes of nAMD. These efforts aim to develop more effective treatments with fewer side effects.\"\n        },\n        {\n            \"summary\": \"The community emphasizes patient education and support.\",\n            \"explanation\": \"Patient education is crucial for empowering individuals with nAMD to understand their condition, make informed decisions about treatment, and manage their symptoms effectively.  This includes providing information on the disease, potential side effects of treatments, and lifestyle modifications that can help improve vision.\"\n        },\n        {\n            \"summary\": \"Collaboration between researchers, clinicians, and patients is essential for advancing nAMD research.\",\n            \"explanation\": \"The success of this community relies heavily on collaboration.  Researchers need to work closely with clinicians to translate research findings into clinical practice. Patients are vital partners in the research process, providing valuable insights and feedback that can help guide future research efforts.\"\n        }\n    ]\n} \n\n\n\n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743304758, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 631, "prompt_tokens": 2048, "total_tokens": 2679, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n49,MA,\"**Macular degeneration** is a condition characterized by the thinning and decreased functionality of the macula, the central part of the retina. This condition is also known as **macular atrophy**. \n\",12\n54,PRECURSOR LESION,,1\n55,PHYSICAL HARMFUL TYPE 3 NEOVASCULARIZATION,,1\n56,EXUDATION OF MNV,,1\n4855,T0,Time point for baseline measurement,1\n2381,T3,T3 is a chemical used in the study,1\n2382,T4,T4 is a chemical used in the study,1\n4856,COCHRAN-ARMITAGE TEST FOR TREND,,1\n1006,CT,\"The **CT** entity refers to both a type of cell line used in research and a measure of subfoveal choroidal thickness, which is the thickness of the tissue at the back of the eye. \n\",1\n53,EXUDATION,,6\n2291,ACTIVE GROUP,Group of eyes exhibiting active changes,6\n2176,IVR,,6\n2183,BCVA,,4\n2184,CMT,,7\n2185,MEDUSA,A specific pattern of visual acuity improvement in patients,3\n2186,SEAFAN,Another specific pattern of visual acuity improvement in patients,3\n2173,CONBERCEPT,\"**CONBERCEPT** is a vascular endothelial growth factor receptor fusion protein medication used in the treatment of **age-related macular degeneration (ARMD)**, **ICNV**, and **tangled MNV patterns**. It is also known by its brand name **IVC**, which is used to treat **non-exudative age-related macular degeneration (nAMD)**.  CONBERCEPT has been found to be a viable treatment option for patients with various eye conditions, including glaucoma. \n\",4\n2175,IVC,,4\n2182,MNV-VD,\"The **MNV-VD** is a measure of visual acuity, as it relates to the study of the ratio between MNV-VD and Charcot-Marie-Tooth disease (CMT). \n\",4\n2294,VESSEL DENSITY,,2\n2295,JUNCTION DENSITY,,2\n2296,NUMBER OF END POINTS,,2\n2297,EXUDATION INCIDENCE RATE,,2\n3301,TREATMENT,\"The **treatment** encompasses various medical procedures and therapies aimed at managing and alleviating diseases.  It can also refer to the specific interventions used for IUAs (In Vitro Fertilization) and PXE (Peroxisomal Disorders). Notably, treatment for PXE is crucial to be initiated early in a child's life. \n\",4\n4857,SD,,1\n5451,NONEXUDATIVE MNV,A condition that causes fluid build-up in the eye,2\n104,RANIBIZUMAB,Humanized anti-VEGF-A antibody fragment,1\n2293,ANASTOMOSIS AND LOOPS,,1\n2292,SILENT GROUP,Group of eyes not exhibiting active changes,5\n3396,PXE,Rare genetic disorder,3\n52,MNV,\"The **MNV** (Macular Neovascularization) is a medical condition characterized by fluid buildup in the body, often caused by physical harm. It can also be a disease and may be related to subretinal fibrosis.  MNV is a model used to assess blood vessel formation and is particularly relevant for studying the effects of extracellular matrix (ECM) on angiogenesis. \n\",5\n4858,PRN,A regimen for intravitreal anti-VEGF injections,2\n4859,INTRAVITREAL ANTI-VEGF INJECTIONS,,2\n5452,DEVELOPED,,1\n4517,SUBRETINAL FIBROSIS,Scarring and thickening of tissue under the retina,1\n3400,LONG-ACTING ANTIV-VEGF,,1\n5200,IOP,\"Intraocular pressure, a measurement of eye pressure\",1\n5211,RNFL THICKNESS,Thickness of the retinal nerve fiber layer,1\n5212,P1 AMPLITUDE DENSITY,Density of the P1 amplitude in the retina,1\n3398,YOUNG AGE,,1\n3399,INTENSIVE TREATMENT NEEDS,,1\n5450,TREATMENT-NAÏVE,Patients who had not received treatment before exudation developed,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n23,MA,NEOVASCULARIZATION,\"MA is a patient who was studied in this research, and the neovascularization process was observed\nMA's condition was studied, and the neovascularization process was observed\",25\n26,MA,PRECURSOR LESION,\"MA lesions were divided into subgroups based on the precursor lesion, which can cause the development and exudation of MNV\",13\n27,MA,PHYSICAL HARMFUL TYPE 3 NEOVASCULARIZATION,The study focused on MA's physical harm from Type 3 neovascularization,13\n28,MA,EXUDATION OF MNV,\"The study focused on MA's exudation of MNV\nThe study focused on the exudation of MNV in MA\",13\n2128,MA,T0,Significant change in MA was observed at T0,13\n2129,MA,T3,Significant increase in MA was observed from T0 to T3,13\n2130,MA,T4,Significant positive correlation between MA and SD values of CMT was observed at T4,13\n2131,MA,COCHRAN-ARMITAGE TEST FOR TREND,Significant reduction in macular IRF and SRF during follow-up,13\n2134,CT,MA,The standard deviation of CT was not statistically significantly different from MA at T4,13\n889,EXUDATION,ACTIVE GROUP,Exudation was observed in the active group,12\n847,IVR,BCVA,\"IVR treatment led to improved BCVA\nIVR treatment led to statistically significant improvement in BCVA\",10\n849,CMT,MEDUSA,\"CMT was associated with a significant decrease in visual acuity on day 90, and the seafan pattern showed improvement\",10\n854,SEAFAN,IVR,\"The Seafan pattern was associated with IVR, which improved the visual acuity of patients\",9\n839,CONBERCEPT,IVC,Conbercept is a medication used to treat nAMD,8\n841,MNV-VD,IVC,Patients with MNV-VD were treated with IVC,8\n844,MNV-VD,BCVA,Improved BCVA was observed in patients with MNV-VD,8\n845,IVC,BCVA,\"IVC treatment led to statistically significant improvement in BCVA\nIVC treatment led to improved BCVA\",8\n892,ACTIVE GROUP,VESSEL DENSITY,\"Active group exhibited greater \"\"vessel density\"\"\",8\n893,ACTIVE GROUP,JUNCTION DENSITY,\"Active group exhibited increased \"\"junction density\"\"\",8\n894,ACTIVE GROUP,NUMBER OF END POINTS,\"Active group had fewer \"\"number of end points\"\"\",8\n895,ACTIVE GROUP,EXUDATION INCIDENCE RATE,Exudation incidence rate was 22.5% in the active group,8\n1384,TREATMENT,BCVA,A drop in BCVA before treatment initiation can predict worse visual outcomes,8\n2132,SD,CMT,Significant positive correlation between SD values of CMT and MA was observed at T4,8\n2402,NONEXUDATIVE MNV,EXUDATION,Exudation development is a risk factor for nonexudative MNV,8\n840,RANIBIZUMAB,IVR,Ranibizumab is a medication used to treat nAMD,7\n891,ACTIVE GROUP,ANASTOMOSIS AND LOOPS,\"Active group exhibited a significantly higher \"\"anastomosis and loops\"\" pattern\",7\n896,SILENT GROUP,VESSEL DENSITY,\"Silent group exhibited less \"\"vessel density\"\"\",7\n1380,PXE,TREATMENT,Most PXE patients require early treatment,7\n2135,MNV,PRN,A PRN regimen for intravitreal anti-VEGF injections is used in MNV type 3,7\n2136,MNV,INTRAVITREAL ANTI-VEGF INJECTIONS,MNV type 3 patients received intravitreal anti-VEGF injections with a PRN regimen,7\n2404,EXUDATION,DEVELOPED,Exudation development was evaluated,7\n852,MEDUSA,SEAFAN,The Medusa and Seafan patterns were both associated with significant changes in visual acuity,6\n1930,SUBRETINAL FIBROSIS,MNV,Subretinal fibrosis may be related to MNV,6\n1385,TREATMENT,LONG-ACTING ANTIV-VEGF,Longer-acting anti-VEGF therapeutics are recommended for PXE patients,5\n2264,CONBERCEPT,IOP,Conbercept treatment affected intraocular pressure,5\n2265,CONBERCEPT,RNFL THICKNESS,Conbercept treatment did not affect retinal nerve fiber layer thickness,5\n2266,CONBERCEPT,P1 AMPLITUDE DENSITY,Conbercept treatment increased P1 amplitude density,5\n1381,PXE,YOUNG AGE,Patients with PXE are young when they need treatment,4\n1382,PXE,INTENSIVE TREATMENT NEEDS,Patients with PXE have intensive treatment needs,4\n2137,PRN,INTRAVITREAL ANTI-VEGF INJECTIONS,A PRN regimen for intravitreal anti-VEGF injections is used in MNV type 3,4\n2401,TREATMENT-NAÏVE,NONEXUDATIVE MNV,Nonexudative MNV patients who had not received treatment before exudation developed,3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_62dba0d086c0bc5fc5f32293ea5d58ceb5970fe335e2f5365faa01da4de0cd5b_v2"}